Literature DB >> 27761850

Patients with Amyotrophic Lateral Sclerosis Have High Interest in and Limited Access to Genetic Testing.

Karin N Wagner1, Haikady Nagaraja2, Dawn C Allain1,3, Adam Quick4, Stephen Kolb4,5, Jennifer Roggenbuck6,7.   

Abstract

Although genetic testing for amyotrophic lateral sclerosis (ALS) is widely available, it is unknown what proportion of patients with ALS have access to genetic counseling and testing, and patient attitudes towards ALS genetic testing have not been studied. We conducted a national survey of ALS patients enrolled in the Agency for Toxic Substances and Disease Registry, which consisted of multiple choice questions and two 12 item Likert scale series assessing respondents' experience with and attitude toward genetic testing. The survey had an 8 % response rate, with 449 completed responses. Genetic testing was offered to 33.4 % and completed by 67.1 % of those offered. A minority of respondents (12.5 %) saw a genetic counselor, and were much more likely to be offered genetic testing (p = 0.0001). Respondents with a family history of ALS (8.4 %) were more likely to be offered testing (p = 0.0001) and complete testing (p = 0.05). Respondents with a family history of ALS were more likely to report a favorable attitude towards genetic testing (p = 0.0003), as were respondents who saw a genetic counselor (p = 0.02). The majority of respondents (82.7 %) felt that genetic testing should be offered to all patients with ALS. Our results indicate that ALS patients may have limited access to genetic testing, but perceive benefit from this service. Development of practice guidelines for genetic testing in ALS, to include the routine offer of genetic counseling, may result in broader and more consistent access to these services.

Entities:  

Keywords:  ALS genetics; Access to care; Amyotrophic lateral sclerosis; Genetic counseling; Genetic testing

Mesh:

Year:  2016        PMID: 27761850     DOI: 10.1007/s10897-016-0034-y

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  18 in total

Review 1.  Amyotrophic lateral sclerosis.

Authors:  L P Rowland; N A Shneider
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  Should all patients with ALS have genetic testing?

Authors:  Kevin Talbot
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-07-18       Impact factor: 10.154

3.  Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period.

Authors:  Daniela Testa; Roberta Lovati; Massimo Ferrarini; Fabrizio Salmoiraghi; Graziella Filippini
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2004-12

4.  Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase.

Authors:  T Juneja; M A Pericak-Vance; N G Laing; S Dave; T Siddique
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

5.  Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interest.

Authors:  Dana Clay Falcone; Elisabeth McCarty Wood; Sharon X Xie; Andrew Siderowf; Vivianna M Van Deerlin
Journal:  J Genet Couns       Date:  2011-04-08       Impact factor: 2.537

6.  "You have shown me my end": attitudes toward presymptomatic testing for familial amyotrophic lateral sclerosis.

Authors:  Joanna H Fanos; Deborah F Gelinas; Robert G Miller
Journal:  Am J Med Genet A       Date:  2004-09-01       Impact factor: 2.802

7.  Familial clustering of ALS in a population-based resource.

Authors:  Summer B Gibson; Karla P Figueroa; Mark B Bromberg; Stefan-M Pulst; Lisa Cannon-Albright
Journal:  Neurology       Date:  2013-12-04       Impact factor: 9.910

Review 8.  Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion.

Authors:  Jamie C Fong; Anna M Karydas; Jill S Goldman
Journal:  Alzheimers Res Ther       Date:  2012-07-19       Impact factor: 6.982

9.  Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors.

Authors:  Jill S Goldman; Susan E Hahn; Jennifer Williamson Catania; Susan LaRusse-Eckert; Melissa Barber Butson; Malia Rumbaugh; Michelle N Strecker; J Scott Roberts; Wylie Burke; Richard Mayeux; Thomas Bird
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

10.  Designing an Internationally Accessible Web-Based Questionnaire to Discover Risk Factors for Amyotrophic Lateral Sclerosis: A Case-Control Study.

Authors:  Jane Alana Parkin Kullmann; Susan Hayes; Min-Xia Wang; Roger Pamphlett
Journal:  JMIR Res Protoc       Date:  2015-08-03
View more
  5 in total

1.  Amyotrophic Lateral Sclerosis Genetic Access Program: Paving the Way for Genetic Characterization of ALS in the Clinic.

Authors:  Jennifer Roggenbuck; Kelly A Rich; Leah Vicini; Marilly Palettas; Joceyln Schroeder; Christina Zaleski; Tara Lincoln; Luke Drury; Jonathan D Glass
Journal:  Neurol Genet       Date:  2021-08-10

2.  The NGS technology for the identification of genes associated with the ALS. A systematic review.

Authors:  Valentina Pecoraro; Jessica Mandrioli; Chiara Carone; Adriano Chiò; Bryan J Traynor; Tommaso Trenti
Journal:  Eur J Clin Invest       Date:  2020-05-19       Impact factor: 5.722

Review 3.  Genetic testing in motor neurone disease.

Authors:  Thanuja Dharmadasa; Jakub Scaber; Evan Edmond; Rachael Marsden; Alexander Thompson; Kevin Talbot; Martin R Turner
Journal:  Pract Neurol       Date:  2022-01-13

Review 4.  Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach.

Authors:  Anne Hogden; Geraldine Foley; Robert D Henderson; Natalie James; Samar M Aoun
Journal:  J Multidiscip Healthc       Date:  2017-05-19

5.  Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing.

Authors:  Karin N Wagner; Haikady N Nagaraja; Dawn C Allain; Adam Quick; Stephen J Kolb; Jennifer Roggenbuck
Journal:  Mol Genet Genomic Med       Date:  2017-12-20       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.